Tonix Pharmaceuticals to Present at BIO-Europe® 2024
Tonix Pharmaceuticals (Nasdaq: TNXP) announced that CEO Seth Lederman will present at BIO-Europe® 2024 on November 4, 2024, at 1:00 p.m. CET in Stockholm, Sweden. The company is developing several key products, including TNX-102 SL for fibromyalgia, which has received FDA Fast Track designation. Their portfolio includes TNX-1300 for cocaine intoxication and TNX-1500 for organ transplant rejection. Notably, Tonix recently secured a contract worth up to $34 million with the U.S. DoD's DTRA to develop TNX-4200, an antiviral agent. The company also markets migraine treatments Zembrace® SymTouch® and Tosymra® through its commercial subsidiary.
Tonix Pharmaceuticals (Nasdaq: TNXP) ha annunciato che il CEO Seth Lederman presenterà al BIO-Europe® 2024 il 4 novembre 2024, alle 13:00 CET a Stoccolma, Svezia. L'azienda sta sviluppando diversi prodotti chiave, incluso TNX-102 SL per la fibromialgia, che ha ricevuto la designazione Fast Track dalla FDA. Il loro portafoglio include TNX-1300 per intossicazione da cocaina e TNX-1500 per il rifiuto dei trapianti d'organo. È importante notare che Tonix ha recentemente ottenuto un contratto del valore di fino a 34 milioni di dollari con la DTRA del Dipartimento della Difesa degli Stati Uniti per sviluppare TNX-4200, un agente antivirale. L'azienda commercializza anche i trattamenti per l'emicrania Zembrace® SymTouch® e Tosymra® attraverso la sua sussidiaria commerciale.
Tonix Pharmaceuticals (Nasdaq: TNXP) anunció que el CEO Seth Lederman presentará en el BIO-Europe® 2024 el 4 de noviembre de 2024, a la 1:00 p.m. CET en Estocolmo, Suecia. La empresa está desarrollando varios productos clave, incluido TNX-102 SL para la fibromialgia, que ha recibido la designación Fast Track de la FDA. Su portafolio incluye TNX-1300 para intoxicación por cocaína y TNX-1500 para el rechazo de trasplantes de órganos. Es importante destacar que Tonix recientemente asegurou un contrato por hasta 34 millones de dólares con la DTRA del Departamento de Defensa de EE. UU. para desarrollar TNX-4200, un agente antiviral. La empresa también comercializa los tratamientos para la migraña Zembrace® SymTouch® y Tosymra® a través de su filial comercial.
토닉스 제약 (Nasdaq: TNXP)는 CEO 세스 레더맨이 2024년 11월 4일 오후 1시 CET에 스웨덴 스톡홀름에서 열리는 BIO-Europe® 2024에서 발표할 것이라고 발표했습니다. 이 회사는 FDA 패스트트랙 지정받은 섬유근육통 치료제를 포함한 여러 주요 제품, TNX-102 SL을 개발하고 있습니다. 그들의 포트폴리오에는 코카인 중독 치료를 위한 TNX-1300과 장기 이식 거부 반응 치료를 위한 TNX-1500이 포함되어 있습니다. 특히, 토닉스는 최근 미국 국방부 DTRA와 최대 3400만 달러 규모의 계약을 체결하여 항바이러스제 TNX-4200을 개발하고 있습니다. 이 회사는 또한 상업 자회사를 통해 편두통 치료제 Zembrace® SymTouch®와 Tosymra®를 판매하고 있습니다.
Tonix Pharmaceuticals (Nasdaq: TNXP) a annoncé que le PDG Seth Lederman fera une présentation au BIO-Europe® 2024 le 4 novembre 2024 à 13h00 CET à Stockholm, en Suède. L'entreprise développe plusieurs produits clés, y compris TNX-102 SL pour la fibromyalgie, qui a reçu la désignation Fast Track de la FDA. Leur portefeuille comprend TNX-1300 pour l'intoxication à la cocaïne et TNX-1500 pour le rejet de greffes d'organes. Il convient de noter que Tonix a récemment obtenu un contrat d'une valeur allant jusqu'à 34 millions de dollars avec la DTRA du Département de la Défense des États-Unis pour développer TNX-4200, un agent antiviral. L'entreprise commercialise également des traitements contre la migraine tels que Zembrace® SymTouch® et Tosymra® par le biais de sa filiale commerciale.
Tonix Pharmaceuticals (Nasdaq: TNXP) gab bekannt, dass CEO Seth Lederman am 4. November 2024 um 13:00 Uhr CET auf der BIO-Europe® 2024 in Stockholm, Schweden, präsentieren wird. Das Unternehmen entwickelt mehrere Schlüsselprodukte, darunter TNX-102 SL zur Behandlung von Fibromyalgie, das die Fast-Track-Designierung der FDA erhalten hat. Ihr Portfolio umfasst TNX-1300 zur Behandlung von Kokainintoxikation und TNX-1500 zur Abstoßung von Organtransplantaten. Bemerkenswert ist, dass Tonix kürzlich einen Vertrag im Wert von bis zu 34 Millionen US-Dollar mit der DTRA des US-Verteidigungsministeriums gesichert hat, um TNX-4200, ein antivirales Mittel, zu entwickeln. Das Unternehmen vertreibt auch Migränemittel wie Zembrace® SymTouch® und Tosymra® über seine kommerzielle Tochtergesellschaft.
- None.
- None.
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET.
To schedule a meeting with the Company’s management at the conference, please submit a meeting request through the partneringOne system or contact brandon.weiner@westwicke.com.
Tonix Pharmaceuticals Holding Corp.*
Tonix is a fully integrated biopharmaceutical company focused on transforming therapies for pain management and modernizing solutions for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders, and its priority is to progress TNX-102 SL, a product candidate for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia. The FDA has granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development designed to treat cocaine intoxication that has FDA Breakthrough Therapy designation and its development is supported by a grant from the U.S. National Institute of Drug Abuse and Addiction. Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease, including TNX-2900 for Prader-Willi syndrome, and infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to
* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.
Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.
This press release and further information about Tonix can be found at www.tonixpharma.com.
Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwicke
peter.vozzo@westwicke.com
(443) 213-0505
Media Contact
Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432
FAQ
When is Tonix Pharmaceuticals (TNXP) presenting at BIO-Europe 2024?
What is the value of Tonix Pharmaceuticals' (TNXP) recent DoD contract?
What products does Tonix Pharmaceuticals (TNXP) currently market?